A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Ustekinumab (Primary) ; Ustekinumab (Primary)
- Indications Inflammatory bowel diseases; Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms UNIFI
- Sponsors Janssen Research & Development
- 28 Nov 2017 Planned End Date changed from 13 Oct 2021 to 26 Nov 2021.
- 06 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Mar 2017 Planned End Date changed from 1 Jul 2021 to 13 Oct 2021.